Humanigen Inc (OTCMKTS:HGEN) CEO Cameron Durrant tells Proactive Investors the California-based biotech has forged a clinical collaboration with Gilead Sciences Inc's (NASDAQ:GILD) subsidiary Kite, to study its therapy lenzilumab, with Kite's drug called Yescarta in patients suffering with certain forms of lymphoma cancer.
Durrant says he expects this Phase 1/2 study to begin by the end of 2019.
Original Article: Humanigen teams up with Kite to treat a type of lymphoma cancer